Integrated early-phase strategy across the cardiometabolic continuum
Dear Kenneth,
Progress in cardiometabolic research demands more than scientific depth. It demands the operational infrastructure and integrated expertise to translate that depth into evidence that regulators can rely on, payers can evaluate, and clinicians can act on.
Most early-phase development still falls short of that standard — not because of weak science, but because the disciplines that need to work together are operating apart. This eBook shows what changes when they do not.
What you will learn
- Why obesity trials are becoming longer, more ethically complex, and more endpoint-intensive — and how the operational model is adapting
- What the shift toward personalised trial design means for cardiometabolic programmes in 2026 and beyond
- How surrogate endpoint acceptability varies across cardiometabolic indications — and what a robust endpoint strategy looks like
- What a realistic, feasible path through early-phase MASLD and diabetic kidney disease development requires
- How integrated infrastructure — specialist clinical sites, advanced laboratory capability, and deep cardiometabolic expertise — changes programme outcomes
Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.
By accessing this content, you are permitting Pharma Ignite or a third party to contact you regarding the content (by phone or email).
© 2026 Marketing Masters Hub. All rights reserved.